Skip to main content


Log in

Analysis of quality of life and late biochemical predictors for localized cancer recurrence following radical prostatectomy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript



Patients with localized prostate cancer (PCa) experience biochemical recurrence (BCR) despite a curatively intended radical prostatectomy (RP). The aim of this study was to describe the quality of life (QoL) of patients with a BCR while identifying predictors of early (ER) and late recurrence (LR).


For this purpose, a total of 330 PCa patients with a BCR following RP at Charité University Hospital in Berlin were analyzed. BCR was defined as two consecutive PSA values ≥ 0.2 after a previous non-detectable level. LR was defined as a BCR after 3 years post-RP. Differences in overall survival (OS) were calculated using the log-rank testing. A logistic regression model was applied to identify predictors of ER and LR. We further evaluated difference between ER and LR with respect to functional outcomes in urinary and sexual domains as well as the patients QoL.


Out of 330 patients, 180 patients showed late BCR. Patients rated their global QoL with 64.5% in ER and 68.8% LR as good (EORTC quality of life Questionnaire, question 29 and 30). The questionnaire did not reveal QoL differences in terms of sexual and urinary function within ER and LR. The main predictor for LR was preoperative serum prostate-specific antigen (PSA) levels with a relative risk (RR) of 0.96 (p = 0.011). OS for patients with LR was significant longer than for patients with ER (154.3 vs. 143.2 months, p = 0.018).


Patients with a BCR show a good quality of life possibly irrespective of the time point of BCR. We further identified preoperative PSA levels as a predictor of LR and noted that patients with LR patients lived longer. Further studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others



Androgen deprivation therapy


Biochemical recurrence


Cancer-specific mortality


Early recurrence


Late recurrence


Laparoscopic radical prostatectomy


Overall survival


Prostate cancer


Prostate cancer-specific survival


Pelvic lymph node dissection


Prostate-specific antigen


PSA doubling time


Positive surgical margin


Quality of life


Radical prostatectomy


Relative risk


Salvage radiation therapy


  1. American Cancer Society. Accessed June 2019

  2. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439

    Article  CAS  Google Scholar 

  3. Tanaka N, Hirayama A, Yoneda T, Yoshida K, Shimada K, Konishi N, Fujimoto K (2013) Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)—a comparison between 2004–2006 and 2007–2009. BMC Cancer 13:588

    Article  Google Scholar 

  4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597

    Article  CAS  Google Scholar 

  5. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376–1383

    Article  Google Scholar 

  6. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59:893–899

    Article  Google Scholar 

  7. Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, Gillessen S, Govorov A, Grummet J, Henry AM, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Van den Broeck T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2018) EAU-ESTRO-ESRU-SIOG guidelines on Prostate Cancer

  8. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M et al (2015) Natural history of surgically treated high-risk prostate cancer. Urol Oncol 33(163):e7–13

    Google Scholar 

  9. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769

    Article  CAS  Google Scholar 

  10. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2004) Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172:S42–S46 (discussion S46–S47)

    PubMed  Google Scholar 

  11. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39

    Article  CAS  Google Scholar 

  12. Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA et al (2015) Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol 67:1160–1167

    Article  Google Scholar 

  13. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165:1146–1151

    Article  CAS  Google Scholar 

  14. Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, Tollefson MK, Gettman MT, Carlson RE, Rangel LJ, Karnes RJ (2016) Standardizing the definition of biochemical recurrence after radical prostatectomy-what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? J Urol 195:1754–1759

    Article  Google Scholar 

  15. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978

    Article  CAS  Google Scholar 

  16. Sowerby RJ, Gani J, Yim H, Radomski SB, Catton C (2014) Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Can Urol Assoc J 8:253–258

    Article  Google Scholar 

  17. Fontaine E, Ben Mouelli S, Thomas L, Otmezguine Y, Beurton D (2004) Urinary continence after salvage radiation therapy following radical prostatectomy, assessed by a self-administered questionnaire: a prospective study. BJU Int 94:521–523

    Article  Google Scholar 

  18. Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, Heysek RV, Jacobsen PB (2016) Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24:2201–2207

    Article  Google Scholar 

Download references


We acknowledge the excellent work of Markus Loos on the Charité prostate cancer database.


The authors received no funding for this work.

Author information

Authors and Affiliations



Conceptualization: JB and AM; data curation: LA; writing: FF and LB; supervision: KM, AM and SH; review and editing: NS and AB.

Corresponding author

Correspondence to Frank Friedersdorff.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

The study involved human participants, but no animals.

Informed consent

We received the written informed consent from all the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedersdorff, F., Buckendahl, L., Alt, L. et al. Analysis of quality of life and late biochemical predictors for localized cancer recurrence following radical prostatectomy. World J Urol 38, 1501–1507 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: